RxDoctor Payments Data

Brian Mahalak

Optometrist · Montgomery, ALNPI 1710148028

Payments from drug & device makers

$1,873in general payments, 2019–2025

Across 69 payments — averaging $27.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bausch & Lomb Americas Inc.$322
  • Alcon$219
  • AbbVie$203
  • Tarsus Pharmaceuticals, Inc.$177
  • Dompe US, Inc.$152
  • Oyster Point Pharma, Inc.$137
  • plus $662 from 13 others

What the payments were for

  • Food & beverage$1,873100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,873 in reported general payments places this provider in the 70th percentile of 749 optometrist providers in Alabama.

See all optometrist providers in Alabama

Medicare billing

Part B allowed, 2024
$150,040
Medicare patients
747
Services billed
1,886

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine18$29,951
Cyclosporine43$28,389
LumiganBimatoprost32$16,850
Latanoprost427$9,802
SimbrinzaBrinzolamide/Brimonidine Tart23$4,865
RocklatanNetarsudil Mesylat/Latanoprost15$4,805
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol13$4,050
Brimonidine Tartrate105$3,482
Prednisolone Acetate59$2,495
Timolol Maleate98$1,610
Dorzolamide Hcl58$1,169
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat54$1,093
ErythromycinErythromycin Base87$1,071
Cephalexin11$119

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$203$46,80150 claims
AlconSimbrinza$219$4,86523 claims
Aerie Pharmaceuticals, Inc.Rocklatan$20$4,80515 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 749 optometrist providers in Alabama.

Other optometrist in Montgomery

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →